Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals

References

• Hepatitis C [Internet]. [cited 2024 Mar 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
   Google Scholar
• Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19(8):533–550. doi: 10.1038/s41575-022-00608-8
   PubMed Web of Science ®Google Scholar
• Global health sector strategy on viral hepatitis. 2016–2021 [Internet]. [cited 2024 Mar 29]. Available from: https://iris.who.int/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1
   Google Scholar
• Brzdęk M, Zarębska-Michaluk D, Invernizzi F, et al. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J Gastroenterol. 2023;29(6):949–966. doi: 10.3748/wjg.v29.i6.949
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Jaroszewicz J, et al. Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. Pol Arch Intern Med. 2020:163–172. doi: 10.20452/pamw.15181
   PubMedGoogle Scholar
• Tabata K, Neufeldt CJ, Bartenschlager R. Hepatitis C virus replication. Cold Spring Harb Perspect Med. 2020;10(3):a037093. doi: 10.1101/cshperspect.a037093
   PubMed Web of Science ®Google Scholar
• Gerold G, Pietschmann T. The HCV life cycle: In vitro tissue culture systems and therapeutic targets. Dig Dis. 2014;32(5):525–537. doi: 10.1159/000360830
   PubMed Web of Science ®Google Scholar
• Geddawy A, Ibrahim YF, Elbahie NM, et al. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5(1):8–17. doi: 10.1515/jtim-2017-0007
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70–86. doi: 10.1053/j.gastro.2016.04.003
   PubMed Web of Science ®Google Scholar
• Wyles D, Bräu N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C Virus in patients coinfected with human immunodeficiency Virus type 1: an open-label, phase 3 study. Clin Infect Dis. 2017;65(1):6–12. doi: 10.1093/cid/cix260
   PubMed Web of Science ®Google Scholar
• Sarrazin C. Treatment failure with DAA therapy: importance of resistance. J Hepatol. 2021;74(6):1472–1482. doi: 10.1016/j.jhep.2021.03.004
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Aronsohn A, Price J, et al. Hepatitis C Guidance 2023 update: American association for the study of liver diseases– infectious diseases society of America recommendations for testing, managing, and treating hepatitis C Virus Infection. Clin Infect Dis. 2023:ciad319. doi: 10.1093/cid/ciad319
   PubMed Web of Science ®Google Scholar
• Howe AYM, Rodrigo C, Cunningham EB, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep. 2022;4(5):100462. doi: 10.1016/j.jhepr.2022.100462
   PubMedGoogle Scholar
• Devan P, Tiong KLA, Neo JE, et al. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral-experienced hepatitis C virus patients: a systematic review and meta-analysis. Viruses. 2023 Jun 30;15(7):1489. doi: 10.3390/v15071489
   PubMed Web of Science ®Google Scholar
• Schulte B, Wübbolding M, Marra F, et al. Frequency of potential drug–drug interactions in the changing field of HCV therapy. Open Forum Infect Dis. 2020;7(2):ofaa040. doi: 10.1093/ofid/ofaa040
   PubMed Web of Science ®Google Scholar
• EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi: 10.1016/j.jhep.2016.09.001
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol. 2020;73(5):1170–1218. doi: 10.1016/j.jhep.2020.08.018
   PubMed Web of Science ®Google Scholar
• Hong J, Wright RC, Partovi N, et al. Review of clinically relevant drug interactions with next generation hepatitis C direct-acting antiviral agents. J Clin Transl Hepatol. 2020;8(3):1–14. doi: 10.14218/JCTH.2020.00034
   PubMed Web of Science ®Google Scholar
• Sandmann L, Schulte B, Manns MP, et al. Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med. 2019;35(3):161–170. doi: 10.1159/000500963
   PubMed Web of Science ®Google Scholar
• [cited 2024 Mar 20]. Available from: https://www.hep-druginteractions.org
   Google Scholar
• Tomasiewicz K, Flisiak R, Jaroszewicz J, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023. Clin Exp Hepatol. 2023;9(1):1–8. doi: 10.5114/ceh.2023.125957
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954. doi: 10.1002/hep.27950
   PubMed Web of Science ®Google Scholar
• EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373–395. doi: 10.1016/j.jhep.2014.05.001
   PubMed Web of Science ®Google Scholar
• Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, et al. Effectiveness and safety of pangenotypic regimens in the most difficult to treat population of genotype 3 HCV infected cirrhotics. J Clin Med. 2021;10(15):3280. doi: 10.3390/jcm10153280
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. doi: 10.1016/j.jhep.2018.03.026
   PubMed Web of Science ®Google Scholar
• Hcv A-I, Panel G, Chung RT, et al. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clinical Infectious Diseases. 2018;67(10):1477–1492.
   PubMed Web of Science ®Google Scholar
• Kao J-H, Heo J, Yoffe B, et al. P1300 efficacy and safety of daclatasvir in combination with asunaprevir (dcv+asv) in cirrhotic and non-cirrhotic patients with hcv genotype 1b: results of the hallmark dual study. J Hepatol. 2014;60(1):S527–S528. doi: 10.1016/S0168-8278(14)61467-7
   Web of Science ®Google Scholar
• Wei L, Wang F-S, Zhang M-X, et al. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol. 2018;24(12):1361–1372. doi: 10.3748/wjg.v24.i12.1361
   PubMed Web of Science ®Google Scholar
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–2091. doi: 10.1002/hep.27113
   PubMed Web of Science ®Google Scholar
• Tam E, Luetkemeyer AF, Mantry PS, et al. Ledipasvir/Sofosbuvir for treatment of hepatitis C virus in sofosbuvir‐experienced, NS 5A treatment‐naïve patients: findings from two randomized trials. Liver Int. 2018;38(6):1010–1021. doi: 10.1111/liv.13616
   PubMed Web of Science ®Google Scholar
• Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1(1):36–44. doi: 10.1016/S2468-1253(16)30002-4
   PubMed Web of Science ®Google Scholar
• Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, et al. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil. Ann Hepatol. 2021;20:100257. doi: 10.1016/j.aohep.2020.09.002
   PubMed Web of Science ®Google Scholar
• Lawitz E, Flisiak R, Abunimeh M, et al. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020;40(5):1032–1041. doi: 10.1111/liv.14320
   PubMed Web of Science ®Google Scholar
• Asselah T, Lee SS, Yao BB, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(1):45–51. doi: 10.1016/S2468-1253(18)30341-8
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Lens S, McPherson S, et al. Efficacy and safety of 8 weeks of glecaprevir/pibrentasvir in treatment-naïve, HCV-Infected patients with APRI ≤ 1 in a single-arm, open-label, multicenter study. Adv Ther. 2019;36(12):3458–3470. doi: 10.1007/s12325-019-01123-0
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–1765. doi: 10.1016/S0140-6736(14)61036-9
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898. doi: 10.1056/NEJMoa1402454
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for Previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493. doi: 10.1056/NEJMoa1316366
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888. doi: 10.1056/NEJMoa1402355
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Affairs National Health Care System Gastroenterology. 2016;151(3):457–471.e5. doi: 10.1053/j.gastro.2016.05.049
   Google Scholar
• Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384(9954):1597–1605. doi: 10.1016/S0140-6736(14)61059-X
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001. doi: 10.1056/NEJMoa1316145
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992. doi: 10.1056/NEJMoa1402338
   PubMed Web of Science ®Google Scholar
• Welzel TM, Asselah T, Dumas EO, et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol. 2017;2(7):494–500. doi: 10.1016/S2468-1253(17)30071-7
   PubMed Web of Science ®Google Scholar
• Petta S, Marzioni M, Russo P, et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017;2(6):427–434. doi: 10.1016/S2468-1253(17)30048-1
   PubMed Web of Science ®Google Scholar
• Chen C-H, Chen C-H, Lin C-L, et al. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep. 2019;9(1):7086. doi: 10.1038/s41598-019-43554-3
   PubMedGoogle Scholar
• Flisiak R, Janczewska E, Wawrzynowicz‐Syczewska M, et al. Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44(9):946–956. doi: 10.1111/apt.13790
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13. doi: 10.7326/M15-0785
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane EJ, Peng C-Y, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164–175.e4. doi: 10.1053/j.gastro.2016.09.045
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44. doi: 10.1056/NEJMoa1208953
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887. doi: 10.1056/NEJMoa1214853
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for Hepatitis C Genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–1877. doi: 10.1056/NEJMoa1214854
   PubMed Web of Science ®Google Scholar
• Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol. 2021;27(11):1006–1021. doi: 10.3748/wjg.v27.i11.1006
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–2617. doi: 10.1056/NEJMoa1512612
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607. doi: 10.1056/NEJMoa1512610
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628. doi: 10.1056/NEJMoa1512614
   PubMed Web of Science ®Google Scholar
• Loo JH, Xu WXF, Low JT, et al. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. WJH. 2022;14(6):1248–1257. doi: 10.4254/wjh.v14.i6.1248
   PubMed Web of Science ®Google Scholar
• Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–1068. doi: 10.1016/S1473-3099(17)30496-6
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369. doi: 10.1056/NEJMoa1702417
   PubMed Web of Science ®Google Scholar
• Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417–426. doi: 10.1016/j.cgh.2017.09.027
   PubMed Web of Science ®Google Scholar
• Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448–1455. doi: 10.1056/NEJMoa1704053
   PubMed Web of Science ®Google Scholar
• Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146. doi: 10.1056/NEJMoa1613512
   PubMed Web of Science ®Google Scholar
• Degasperi E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019;71(6):1106–1115. doi: 10.1016/j.jhep.2019.07.020
   PubMed Web of Science ®Google Scholar
• Xie J, Xu B, Wei L, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis. Infect Dis Ther. 2022;11(4):1661–1682. doi: 10.1007/s40121-022-00666-0
   PubMed Web of Science ®Google Scholar
• El-Kassas M, Emadeldeen M, Hassany M, et al. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C. J Hepatol. 2023;79(2):314–320. doi: 10.1016/j.jhep.2023.04.011
   PubMed Web of Science ®Google Scholar
• Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371–378. doi: 10.1002/hep.28995
   PubMed Web of Science ®Google Scholar
• Indolfi G, Hierro L, Dezsofi A, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the hepatology committee of European society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):505–515. doi: 10.1097/MPG.0000000000001872
   PubMed Web of Science ®Google Scholar
• AASLD HCV guidance: recommendations for testing, managing, and treating hepatitis C. HCV in children. Available from: https://www.hcvguidelines.org/unique-populations/children.
   Google Scholar
• Honegger JR, Gowda C. Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children. Curr Opin Infect Dis. 2022;35(5):468–476. doi: 10.1097/QCO.0000000000000856
   PubMed Web of Science ®Google Scholar
• Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. [Internet]. [cited 2024 Mar 29]. Available from: https://www.who.int/publications/i/item/9789240053779
   Google Scholar
• Pawlowska M, Dobrowolska K, Moppert J, et al. Real-world efficacy and safety of an 8-week glecaprevir/pibrentasvir regimen in children and adolescents with chronic hepatitis C—results of a multicenter EpiTer-2 study. J Clin Med. 2023;12(21):6949. doi: 10.3390/jcm12216949
   PubMed Web of Science ®Google Scholar
• El-Sayed MH, Indolfi G. Hepatitis C virus treatment in children: a challenge for hepatitis C virus elimination. Semin Liver Dis. 2020;40(3):213–224. doi: 10.1055/s-0040-1708812
   PubMed Web of Science ®Google Scholar
• Kushner T, Djerboua M, Biondi MJ, et al. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. J Hepatol. 2022;77(5):1256–1264. doi: 10.1016/j.jhep.2022.05.016
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87. doi: 10.1002/hep.27259
   PubMed Web of Science ®Google Scholar
• Moraes Coelho HS, Villela-Nogueira CA. Predictors of response to chronic hepatitis C treatment. Ann Hepatol. 2010;9(Suppl):54–60. doi: 10.1016/S1665-2681(19)31725-9
   PubMedGoogle Scholar
• Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002;36:136. doi: 10.1016/S0168-8278(02)80488-3
   Web of Science ®Google Scholar
• Flisiak R, Zarębska‐Michaluk D, Janczewska E, et al. Treatment of HCV infection in Poland at the beginning of the interferon‐free era—the EpiTer‐2 study. J Viral Hepat. 2018;25(6):661–669. doi: 10.1111/jvh.12861
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149(6):1462–1470. doi: 10.1053/j.gastro.2015.07.043
   PubMed Web of Science ®Google Scholar
• Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int. 2020;40(8):1841–1852. doi: 10.1111/liv.14537
   PubMed Web of Science ®Google Scholar
• Rosati S, Wong A, Marco VD, et al. Real-world Effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings. Future Virol. 2022;17(7):419–428. doi: 10.2217/fvl-2022-0016
   Web of Science ®Google Scholar
• Flamm S, Mutimer D, Asatryan A, et al. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2/3 analysis. J Viral Hepat. 2019;26(3):337–349. doi: 10.1111/jvh.13038
   PubMed Web of Science ®Google Scholar
• Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112–1121. doi: 10.1016/j.jhep.2020.01.025
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379–387. doi: 10.1016/j.jhep.2018.11.011
   PubMed Web of Science ®Google Scholar
• Vermehren J, Serfert Y, Cornberg M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: results from the German hepatitis C-Registry (DHC-R). Z Gastroenterol. 2020;58(9):841–846. doi: 10.1055/a-1217-7669
   PubMedGoogle Scholar
• Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73(3):540–548. doi: 10.1016/j.jhep.2020.03.031
   PubMed Web of Science ®Google Scholar
• Wong YJ, Tran S, Huang C-F, et al. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatol Int. 2023;17(5):1150–1161. doi: 10.1007/s12072-023-10547-4
   PubMed Web of Science ®Google Scholar
• Patel S, Martin MT, Flamm SL. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int. 2021;41(12):3024–3027. doi: 10.1111/liv.15075
   PubMed Web of Science ®Google Scholar
• Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131–1140.e5. doi: 10.1053/j.gastro.2016.08.004
   PubMed Web of Science ®Google Scholar
• Foster GR, Irving WL, Cheung MCM, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224–1231. doi: 10.1016/j.jhep.2016.01.029
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65(3):777–788. doi: 10.1002/hep.28926
   PubMed Web of Science ®Google Scholar
• Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5(7):649–657. doi: 10.1016/S2468-1253(20)30081-9
   PubMed Web of Science ®Google Scholar
• El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154(8):2111–2121.e8. doi: 10.1053/j.gastro.2018.03.022
   PubMed Web of Science ®Google Scholar
• Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808. doi: 10.1016/S1473-3099(15)00485-5
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for Previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221. doi: 10.1056/NEJMoa1306218
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Orkin C, Viani RM, et al. Safety and efficacy of Ombitasvir, paritaprevir with ritonavir ± dasabuvir with or without ribavirin in patients with human immunodeficiency virus-1 and hepatitis C virus genotype 1 or genotype 4 Coinfection: TURQUOISE-I part 2. Open Forum Infect Dis. 2017;4(3):ofx154. doi: 10.1093/ofid/ofx154
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of Glecaprevir/Pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67(7):1010–1017. doi: 10.1093/cid/ciy220
   PubMed Web of Science ®Google Scholar
• Bischoff J, Mauss S, Cordes C, et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med. 2018;19(4):299–307. doi: 10.1111/hiv.12579
   PubMed Web of Science ®Google Scholar
• Milazzo L, Lai A, Calvi E, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV / HIV -coinfected patients: real-life safety and efficacy. HIV Med. 2017;18(4):284–291. doi: 10.1111/hiv.12429
   PubMed Web of Science ®Google Scholar
• López-Huertas MR, Palladino C, Garrido-Arquero M, et al. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. Sci Rep. 2019;9(1):5606. doi: 10.1038/s41598-019-41788-9
   PubMedGoogle Scholar
• Gobran ST, Pagliuzza A, Khedr O, et al. DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people. J Virol. 2023;97(12):e01105–23.
   PubMed Web of Science ®Google Scholar
• Ryscavage P, Hussien S, Seung H, et al. CD4+ T‐cell recovery in HIV/hepatitis C co‐infected patients following successful hepatitis C treatment. HIV Med. 2024;25(5):622–627. doi: 10.1111/hiv.13612
   PubMed Web of Science ®Google Scholar
• Zarębska-Michaluk D, Brzdęk M, Rzymski P, et al. Hepatitis B virus coinfection in patients treated for chronic hepatitis C: Clinical characteristics, risk of reactivation with long-term follow-up and effectiveness of antiviral therapy. Pol Arch Intern Med. 2024:16638. doi: 10.20452/pamw.16638
   PubMedGoogle Scholar
• Gamal Eldeen H, Hassany M, Elakel W, et al. Seroprevalence of HBV/HCV coinfection among patients with HCV screened during the national campaign for HCV eradication in Egypt. Arab J Gastroenterol. 2022;23(4):259–262. doi: 10.1016/j.ajg.2022.06.006
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 2004;127(5):S35–S50. doi: 10.1053/j.gastro.2004.09.014
   PubMed Web of Science ®Google Scholar
• Papadopoulos N. Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues. Ann Gastroenterol. 2018;365–370. doi: 10.20524/aog.2018.0255
   PubMedGoogle Scholar
• Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43(1):100–107. doi: 10.1002/hep.20944
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P, et al. Pegylated Interferon mono‐therapy of chronic hepatitis C in the dialysis population: systematic review and meta‐analysis. Ther Apher Dial. 2015;19(6):611–621. doi: 10.1111/1744-9987.12318
   PubMed Web of Science ®Google Scholar
• Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/Velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71(4):660–665. doi: 10.1016/j.jhep.2019.05.028
   PubMed Web of Science ®Google Scholar
• Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. Liver Int. 2016;36(6):807–816. doi: 10.1111/liv.13102
   PubMed Web of Science ®Google Scholar
• Chute DF, Chung RT, Sise ME. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney Int. 2018;93(3):560–567. doi: 10.1016/j.kint.2017.10.024
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Berak H, et al. Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals. Clin Exp Hepatol. 2023;9(3):193–201. doi: 10.5114/ceh.2023.130935
   PubMed Web of Science ®Google Scholar
• Schmitt A, Günther R, Mauss S, et al. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R). Z Gastroenterol. 2020;58(4):341–351. doi: 10.1055/a-1068-3056
   PubMed Web of Science ®Google Scholar
• Hepatitis C annual epidemiological report for 2021 [Internet]. [cited 2024 Mar 29]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER-HEP-C-2021.pdf
   Google Scholar
• Muller A, Vlahov D, Akiyama MJ, et al. Hepatitis C reinfection in people who inject drugs in resource-limited countries: a systematic review and analysis. Int J Environ Res Public Health. 2020;17(14):4951. doi: 10.3390/ijerph17144951
   PubMed Web of Science ®Google Scholar
• Yeung A, Palmateer NE, Dillon JF, et al. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol. 2022;76(3):549–557. doi: 10.1016/j.jhep.2021.09.038
   PubMed Web of Science ®Google Scholar
• Heo M, Norton BL, Pericot-Valverde I, et al. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study. J Hepatol. 2024;80(5):702–713.
   PubMed Web of Science ®Google Scholar
• Norton BL, Akiyama MJ, Agyemang L, et al. Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents. Open Forum Infect Dis. 2020;7(10):ofaa377. doi: 10.1093/ofid/ofaa377
   PubMed Web of Science ®Google Scholar
• Frankova S, Jandova Z, Jinochova G, et al. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J. 2021;18(1):69. doi: 10.1186/s12954-021-00519-y
   PubMed Web of Science ®Google Scholar
• EU Action Plan on drugs. 2017-2020 [Internet]. [cited 2024 Mar 29]. Available from: https://www.emcdda.europa.eu/drugs-library/eu-action-plan-drugs-2017-2020_en
   Google Scholar
• Munari SC, Traeger MW, Menon V, et al. Determining reinfection rates by hepatitis C testing interval among key populations: a systematic review and meta‐analysis. Liver Int. 2023;43(12):2625–2644. doi: 10.1111/liv.15705
   PubMed Web of Science ®Google Scholar
• Ingiliz P, Wehmeyer MH, Boesecke C, et al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: current incidence rates, compared with rates during the interferon era. Clin Infect Dis. 2020;71(5):1248–1254. doi: 10.1093/cid/ciz949
   PubMed Web of Science ®Google Scholar
• Jin F, Dore GJ, Matthews G, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(1):39–56. doi: 10.1016/S2468-1253(20)30303-4
   PubMed Web of Science ®Google Scholar
• Garvey LJ, Cooke GS, Smith C, et al. Decline in Hepatitis C Virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: progress to HCV microelimination in the United Kingdom? Clin Infect Dis. 2021;72(2):233–238. doi: 10.1093/cid/ciaa021
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Sobrino‐Vegas P, Monge S, et al. Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. J Viral Hepat. 2015;22(5):496–503. doi: 10.1111/jvh.12353
   PubMed Web of Science ®Google Scholar
• Jachs M, Binter T, Chromy D, et al. Outcomes of an HCV elimination program targeting the Viennese MSM population. Wien Klin Wochenschr. 2021;133(13–14):635–640. doi: 10.1007/s00508-021-01898-9
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Berak H, et al. Treatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population. Pol Arch Intern Med. 2024;16644. doi: 10.20452/pamw.16644
   Google Scholar
• Zhang W, Zhang J, Tang S, et al. Efficacy and safety of sofosbuvir-based regimens in hepatitis C patients with decompensated cirrhosis: a systematic review and meta-analysis. J Clin Transl Hepatol. 2022;000–000. doi: 10.14218/JCTH.2022.00006
   Web of Science ®Google Scholar
• Fabbiani M, Lombardi A, Colaneri M, et al. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting. J Viral Hepat. 2021;28(3):558–568. doi: 10.1111/jvh.13454
   PubMed Web of Science ®Google Scholar
• Fiore V, Manca V, Colpani A, et al. Facing HCV as a major public healthcare threat in Italy: epidemiology and micro-elimination pathways among underserved populations. Healthcare (Basel). 2023;11(14):2109. doi: 10.3390/healthcare11142109
   PubMedGoogle Scholar
• Flisiak R, Zarębska-Michaluk D, Ciupkeviciene E, et al. HCV elimination in central Europe with particular emphasis on microelimination in prisons. Viruses. 2022;14(3):482. doi: 10.3390/v14030482
   PubMed Web of Science ®Google Scholar
• Woyesa SB, Amente KD. Hepatitis C virus dynamic transmission models among people who inject drugs. Infect Drug Resist. 2023;16:1061–1068. doi: 10.2147/IDR.S403133
   PubMed Web of Science ®Google Scholar
• Mendlowitz AB, Bremner KE, Krahn M, et al. Characterizing the cascade of care for hepatitis C virus infection among status first nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023;195(14):E499–E512. doi: 10.1503/cmaj.220717
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Villota-Rivas M, Fernández I, et al. A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. Commun Med (Lond). 2022;2(1):20. doi: 10.1038/s43856-022-00077-9
   PubMedGoogle Scholar
• Thomas DL, Owen A, Kiser JJ. Prospects for long-acting treatments for hepatitis C. Clin Infect Dis. 2022;75(Supplement_4):S525–S529. doi: 10.1093/cid/ciac715
   PubMedGoogle Scholar
• Verma M, Chu JN, Salama JAF, et al. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Proc Natl Acad Sci, USA. 2020;117(22):11987–11994. doi: 10.1073/pnas.2004746117
   PubMed Web of Science ®Google Scholar
• Torresi J, Johnson D, Wedemeyer H, et al. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273–1285. doi: 10.1016/j.jhep.2010.09.040
   PubMed Web of Science ®Google Scholar
• Abbasi F, Almukhtar M, Fazlollahpour-Naghibi A, et al. Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis. eClinicalmedicine. 2023;66:102327. doi: 10.1016/j.eclinm.2023.102327
   PubMedGoogle Scholar
• El-Shabrawi MHF, Kamal NM, Mogahed EA, et al. Perinatal transmission of hepatitis C virus: an update. Arch Med Sci. 2020;16(6):1360–1369. doi: 10.5114/aoms.2019.83644
   PubMed Web of Science ®Google Scholar
• Catherine C, Charles J, Smid M, et al. Safety and efficacy of SOF/VEL during pregnancy: interim analysis of the STORC study. Poster #5018-C.
   Google Scholar
• He S, Lockart I, Alavi M, et al. Systematic review with meta‐analysis: effectiveness of direct‐acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51(1):34–52. doi: 10.1111/apt.15598
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Janczewska E, et al. Five-year follow-up of cured HCV patients under real-world interferon-free therapy. Cancers (Basel). 2021;13(15):3694. doi: 10.3390/cancers13153694
   PubMed Web of Science ®Google Scholar
• Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142–156.e2. doi: 10.1053/j.gastro.2016.09.009
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264–1278.e4. doi: 10.1053/j.gastro.2019.07.033
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733. doi: 10.1016/j.jhep.2016.06.015
   PubMed Web of Science ®Google Scholar
• Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis c infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156(8):2149–2157. doi: 10.1053/j.gastro.2019.02.046
   PubMed Web of Science ®Google Scholar
• Razavi H, Sanchez Gonzalez Y, Yuen C, et al. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40(3):522–529. doi: 10.1111/liv.14324
   PubMed Web of Science ®Google Scholar
• Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of Glecaprevir/Pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology. 2020;71(2):456–462. doi: 10.1002/hep.30840
   PubMed Web of Science ®Google Scholar